A Relative Bioavailability Study of LY3209590 in Healthy Participants

Eli Lilly and Company168 enrolled

Overview

The study will be conducted in two parts (part A and part B). The main purpose of this study is to compare the amount of LY3209590 that gets into the blood stream and how long it takes the body to get rid of it, when self-administered at different body sites, abdominal wall, upper arm and thigh (part A), when administered by two different routes of injection, subcutaneously or intravenously (part B) in healthy participants. The study may last up to 65 (part A) and 184 (part B) days, respectively.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

168

Conditions

Healthy

Interventions

LY3209590 (SC)DRUG

Administered SC.

LY3209590 (IV)DRUG

Administered IV.

Eligibility

Sex: ALLMin age: 21 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female participants who are overtly healthy as determined by medical evaluation * Participants with body mass index (BMI) within the range 18.5 to 35.0 kilograms per meter squared (kg/m²) * Male or female participants must agree to use contraception Exclusion Criteria: * Have a history of multiple or severe allergic reactions or a history of severe anaphylactic reaction * Have known allergies to LY3209590, related compounds, or any components of the formulation * Have an abnormality in the 12-lead electrocardiogram * Intend to use prescription medication, including herbal medications and traditional medications * Show evidence of human immunodeficiency virus infection or positive human immunodeficiency virus antibodies, hepatitis C or positive hepatitis C antibody, or hepatitis B or positive hepatitis B surface antigen * Are lactating or pregnant

Locations (1)

Lilly Centre for Clinical Pharmacology

Singapore, Singapore

Outcomes

Primary Outcomes

Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3209590

Part A: PK: AUC0-∞ of LY3209590

Time frame: Predose on Day 1 through Day 65

Secondary Outcomes

Part B: PK: AUC0-∞ of LY3209590

Time frame: Predose on Day 1 through Day 65

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.